Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04883905 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Study acronym: ELEVATE
StatusRecruiting
PhaseNot specified
Started2021-04-26
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 44 months later Apr 1, 2027 → Dec 31, 2030
See other at-risk trials from Alnylam Pharmaceuticals

Amendment history

The 50 most recent of 54 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-04
Study Status v53
Primary completion pushed: 2027-04-01 → 2030-12-31
Completion pushed: 2027-04-01 → 2030-12-31
2026-04-23
Study Status v52
Re-verified, no change to tracked fields
2026-02-13
Study Status, Contacts/Locations v51
Study sites29→30
2025-12-18
Study Status, Contacts/Locations v50
Study sitesdetails revised at 1 of 29 sites
2025-11-12
Study Status v49
Re-verified, no change to tracked fields
Show 45 earlier versions
2025-10-15
Study Status, Contacts/Locations v48
Study sites28→29
2025-09-17
Study Status, Contacts/Locations v47
Study sitesdetails revised at 1 of 28 sites
2025-08-25
Study Status, Contacts/Locations v46
Study sitesdetails revised at 2 of 28 sites
2025-07-15
5 amendments v41-v45
5 re-verifications since 2025-01-08, no change to tracked fields
2024-12-04
Study Status, Contacts/Locations v40
Study sites27→28
2024-11-07
Study Status, Contacts/Locations v39
Study sites26→27
2024-10-02
3 amendments v36-v38
3 re-verifications since 2024-08-06, no change to tracked fields
2024-07-22
Study Status, Oversight, Contacts/Locations v35
Primary completion date2027-04→2027-04-01
Completion date2027-04→2027-04-01
Study sites25→26
2024-06-25
Study Status v34
Re-verified, no change to tracked fields
2024-05-09
Study Status, Contacts/Locations v33
Study sites24→25
2024-04-17
Study Status, Contacts/Locations v32
Study sites23→24
2024-03-08
4 amendments v28-v31
4 re-verifications since 2023-12-12, no change to tracked fields
2023-11-14
Study Status, Contacts/Locations v27
Study sites22→23
2023-10-20
11 amendments v16-v26
11 re-verifications since 2022-09-12, no change to tracked fields
2022-08-11
Study Status, Contacts/Locations v15
Study sites21→22
2022-07-12
Study Status v14
Re-verified, no change to tracked fields
2022-06-15
Study Status, Contacts/Locations v13
Study sites20→21
2022-05-06
Study Status v12
Re-verified, no change to tracked fields
2022-04-11
Study Status, Contacts/Locations v11
Study sites19→20
2022-03-10
Study Status, Contacts/Locations v10
Study sites15→19
2022-02-10
Study Status, Contacts/Locations v9
Study sites13→15
2022-01-11
Study Status v8
Re-verified, no change to tracked fields
2021-12-13
Study Status, Contacts/Locations v7
Study sites12→13
2021-11-09
Study Status, Contacts/Locations v6
Study sites10→12
2021-10-14
Study Status, Contacts/Locations v5
Study sites9→10
2021-09-15
Study Status, Contacts/Locations v4
Study sites2→9
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Trial Details
NCT Number NCT04883905
Lead Sponsor Alnylam Pharmaceuticals
Conditions Acute Hepatic Porphyria
Enrollment 150 participants
Start Date 2021-04-26
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-08